Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications
Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Alessandro Rizzo, Francesca Ambrogio, Matteo Centonze, Annalisa Schirizzi, G Leonardis, Rosalba D’Alessandro, Claudio Lotesoriere, Gianluigi Giannelli
Abstract
gene. ATX is a secreted glycoprotein and catalyzes the hydrolysis of lysophosphatidylcholine to lysophosphatidic acid (LPA). LPA is responsible for the transduction of various signal pathways through the interaction with at least six G protein-coupled receptors, LPA Receptors 1 to 6 (LPAR1-6). The ATX-LPA axis is involved in various physiological and pathological processes, such as angiogenesis, embryonic development, inflammation, fibrosis, and obesity. However, significant research also reported its connection to carcinogenesis, immune escape, metastasis, tumor microenvironment, cancer stem cells, and therapeutic resistance. Moreover, several studies suggested ATX and LPA as relevant biomarkers and/or therapeutic targets. In this review of the literature, we aimed to deepen knowledge about the role of the ATX-LPA axis as a promoter of cancer development, progression and invasion, and therapeutic resistance. Finally, we explored its potential application as a prognostic/predictive biomarker and therapeutic target for tumor treatment.